List of Doryx drug patents

Doryx is owned by Mayne Pharma.

Doryx contains Doxycycline Hyclate.

Doryx has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Doryx are:

  • US6958161

Doryx was authorised for market use on 06 May, 2005.

Doryx is available in tablet, delayed release;oral dosage forms.

Doryx can be used as to treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet.

The generics of Doryx are possible to be released after 23 December, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161 MAYNE PHARMA Modified release coated drug preparation
Dec, 2022

(a month ago)

US8715724 MAYNE PHARMA Tabletting process
Feb, 2028

(5 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(11 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in